113 results about "Fatty acid biosynthesis" patented technology

The present invention is directed to nucleic acid molecules and nucleic acid constructs, and other agents associated with fatty acid synthesis, particularly the ratios of saturated and unsaturated fats. Moreover, the present invention is directed to plants incorporating such agents where the plants exhibit altered ratios of saturated and unsaturated fats. In particular, the present invention is directed to plants incorporating such agents where the plants exhibit altered levels of saturated and unsaturated fatty acids.

The present invention is directed to nucleic acid molecules and nucleic acid constructs, and other agents associated with fatty acid synthesis, particularly the ratios of saturated and unsaturated fats. Moreover, the present invention is directed to plants incorporating such agents where the plants exhibit altered ratios of saturated and unsaturated fats. In particular, the present invention is directed to plants incorporating such agents where the plants exhibit altered ratios of monounsaturated to polyunsaturated fatty acids.

The present invention is in the field of plant genetics and provides recombinant nucleic acid molecules, constructs, and other agents associated with the coordinate manipulation of multiple genes in the fatty acid synthesis pathway. In particular, the agents of the present invention are associated with the simultaneous enhanced expression of certain genes in the fatty acid synthesis pathway and suppressed expression of certain other genes in the same pathway. Also provided are plants incorporating such agents, and in particular plants incorporating such constructs where the plants exhibit altered seed oil compositions.

Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or genes associated with fatty acid biosynthesis, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.

The present invention relates to the isolation, purification, characterization and use of a mitochondrial pyruvate dehydrogenase kinase (PDHK) gene [SEQ ID NO:1](pYA5; ATCC No 209562) from the Brassicaceae (specifically Arabidopsis thaliana). The invention includes isolated and purified DNA of the stated sequence and relates to methods of regulating fatty acid synthesis, seed oil content, seed size/weight, flowering time, vegetative growth, respiration rate and generation time using the gene and to tissues and plants transformed with the gene. The invention also relates to transgenic plants, plant tissues and plant seeds having a genome containing an introduced DNA sequence of SEQ ID NO:1; or a part of SEQ ID NO:1 characterized in that said sequence has been introduced into an antisense or sense orientation, and a method of producing such plants and plant seeds. The invention also relates to substantially homologous DNA sequences from plants encoding proteins with deduced amino acid sequences of 25% or greater identity, and 50% or greater similarity, isolated and/or characterized by known methods using the sequence information of SEQ ID NO:1, and to parts of reduced length that are still able to function as inhibitors of gene expression by use in an anti-sense, co-suppression or other gene silencing technologies.

The present invention relates to the isolation, purification, characterization and use of the plant Snf1-related protein kinase (SnRK) gene and genetic products. The invention includes isolated and purified SnRK DNA and relates to methods of regulating water loss and plant drought tolerance, sucrose content, starch content, seed oil content, fatty acid synthesis, seed oil acyl composition, seed size/weight, resistance/tolerance to biotic stresses, increased root biomass, and/or carbon flux into other seed components, plant, using the gene, and to tissues and plants transformed with the gene. The invention also relates to transgenic plants, plant tissues and plant seeds having a genome containing an introduced DNA sequence of the invention, and a method of producing such plants and plant seeds.

The invention provides a regulation and control method for improving the EPA (Eicosapentaenoic Acid) content in schizochytrium and application and relates to marine microorganisms. A strain schizochytrium sp. MYA1381 is subjected to flat plate and second-grade seed activation to prepare a seed solution; then the strain is inoculated to a fermentation culture medium; fluridone is added at differentphases of the growth of the schizochytrium. The fluridone can be applied to improvement of the EPA content in the schizochytrium. The fluridone is applied to regulation and control of a fatty acid synthesis way for the first time and a new thought is provided for improving the EPA content in the schizochytrium. The fluridone is added and the content of EPA in schizochytrium grease is remarkably improved and is improved by 42.31 percent when being compared with a manner without the fluridone. A foundation is provided for improving the EPA content in the schizochytrium by utilizing the fluridone.

The present invention describes the identification and isolation of chromones and novel chromone compositions from plant sources that exhibit up-regulation of adiponectin production by adipocytes and the normalization of virtually hundreds of genes related to glucose and fatty acid metabolic and signaling pathways. The chromone compositions are effective in enhancing adiponectin production by adipocytes and regulating genes involved in fatty acid biosynthesis, mitochondrial β-oxidation of fatty acids, steroid biosynthesis, gluconeogenesis, fat transport, PPARα/RXRα liver signaling and xenobiotic metabolism. The chromone compositions can be used to increase insulin sensitivity, improve glucose tolerance, lower triglyceride levels and balance glucose levels in mammals. Included in the present invention are methods for the prevention and treatment of a variety of diseases and conditions including, but not limited to insulin resistance, glucose intolerance, hyperglycemia, metabolic syndromes, dyslipidemia, and hypertriglyceridemia.